TargetBeta
IL3RA
interleukin 3 receptor subunit alpha · also CD123 · CD molecules
2 programs in company-led studies act on IL3RA, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| pivekimab sunirinerule | AbbVie | phase 3 | 44 running | – | ChEMBL |
| relmapirazinrule | MediBeacon | phase 3 | 82 running | – | NCIt |
Conditions their studies are in
- Blastic Plasmacytoid Dendritic Cell Neoplasm, 2 programs
- Acute Kidney Injury, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Renal Insufficiency, 1 program
- Renal Insufficiency, Chronic, 1 program
- Retinal Diseases, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026relmapirazin · MediBeacon · phase 3 · NCT07080008
- Feb 2027pivekimab sunirine · AbbVie · phase 3 · NCT04086264
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.